[EN] USE OF THIAZOLOIMIDAZOLES, THIAZOLOTETRAZOLES AND THIAZOLOTRIAZOLES AS MGLUR5 ANTAGONISTS [FR] UTILISATION DE THIAZOLOIMIDAZOLES, DE THIAZOLOTÉTRAZOLES ET DE THIAZOLOTRIAZOLES COMME ANTAGONISTES DE MGLUR5
Negative allosteric modulators of MGLUR5 for use in the treatment of mature brain damages
申请人:Sinntaxis AB
公开号:US11033545B2
公开(公告)日:2021-06-15
The present disclosure relates to the use of negative allosteric modulators (NAMs) of the metabotropic glutamate receptor 5 (mGluR5) in the treatment of a mature brain damage, such as damage after stroke.
The identification of novel orally active mGluR5 antagonist GSK2210875 is described. (C) 2010 Elsevier Ltd. All rights reserved.
[EN] USE OF THIAZOLOIMIDAZOLES, THIAZOLOTETRAZOLES AND THIAZOLOTRIAZOLES AS MGLUR5 ANTAGONISTS<br/>[FR] UTILISATION DE THIAZOLOIMIDAZOLES, DE THIAZOLOTÉTRAZOLES ET DE THIAZOLOTRIAZOLES COMME ANTAGONISTES DE MGLUR5
申请人:GLAXO GROUP LTD
公开号:WO2009087220A1
公开(公告)日:2009-07-16
The invention relates to the use of thiazolotriazole, thiazoloimidazole and thiazolotetrazole derivatives of formula (I) in treating diseases and conditions for which antagonism of the mGluR5 receptor is beneficial, in particular substance related disorders. The invention also relates to certain novel derivatives. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.